<?xml version="1.0" encoding="UTF-8"?>
<GaPExchange xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:noNamespaceSchemaLocation="./dbGaPEx2.1.5.xsd">

<MetaVariables>
	<Submitter/>
	<Method/>
</MetaVariables>
<MetaLinks/>

<Projects>
	<Project/>
</Projects>

<Studies>

<Study source="dbGaP" accession="phs000182.v2.p1" parentStudy="phs000182.v2.p1" createDate="2010-03-22" modDate="2011-11-22">

<Configuration>
	<Data_Provider><![CDATA[
		<table border="1">
		<tr><th>Title</th><th>Name</th><th>Institute</th></tr>
		<tr><td>Principal Investigator</td><td>Anand Swaroop, PhD</td><td>National Eye Institute, National Institutes of Health, Bethesda, MD, USA; University of Michigan, Ann Arbor, MI, USA</td></tr>
		<tr><td>Co-Principal Investigators</td><td>Gon&#231;alo Abecasis, PhD</td><td>University of Michigan, Ann Arbor, MI, USA</td></tr>
		<tr><td>Co-Principal Investigators</td><td>Dwight Stambolian, MD, PhD</td><td>University of Pennsylvania, Philadelphia, PA, USA</td></tr>
		<tr><td>Co-Principal Investigators</td><td>Albert Edwards, MD, PhD</td><td>Mayo Clinic, Rochester, MN, USA</td></tr>
		<tr><td>Co-Investigators</td><td>John Heckenlively, MD</td><td>University of Michigan, Ann Arbor, MI, USA</td></tr>
		</table>
	]]></Data_Provider>
	<StudyNameEntrez>AMD-MMAP Cohort Study: A Joint Genome Wide Association Study</StudyNameEntrez>
	<StudyNameReportPage>Age related Macular Degeneration (AMD)-- Michigan, Mayo, AREDS, Pennsylvania (MMAP) Cohort Study: A Joint Genome Wide Association Study</StudyNameReportPage>
	<StudyTypes>
		<StudyType>Case-Control</StudyType>
	</StudyTypes>
	<Description><![CDATA[
<p>Age-related Macular Degeneration (AMD) is a leading cause of incurable blindness in people over the age of 65.  AMD is a 	late-onset multi-factorial neurodegenerative disease and its pathogenesis involves interaction of 	genetic and environmental factors.  Several chromosomal regions have been associated with AMD susceptibility through linkage 	analysis (<a href="http://www.ncbi.nlm.nih.gov/pubmed/19405847">Swaroop et al., 2009</a>).  More recent studies provide 	strong evidence that variants within the CFH gene cluster on chromosome 1 and at/near LOC387715/ARMS2 on chromosome 10 are 	strongly associated with disease.  Variants at other genes including C2/BF, C3, CFI and APOE4, also contribute to AMD susceptibility.</p> 	<p>Our primary goals are to identify genetic variants and haplotypes that are associated with AMD.  The underlying hypothesis 	is that DNA variation(s) in multiple genetic susceptibility loci will predispose individuals to AMD pathogenesis, and comparison 	of DNA of cases and controls should identify these susceptibility variants.  Our studies are focused on the genetic 	analysis of advanced AMD and should provide novel insights into disease diagnosis, progression and pathology.</p> 	<p>We have assembled a collaborative group of researchers from the University of Michigan, Mayo Clinic, 	University of Pennsylvania, and the AREDS group including National Eye Institute intramural investigators, who collected clinical data 	and DNA from a large number of patients affected with AMD and from unaffected controls.  The primary source of funding was National Eye 	Institute.  Through this collaborative effort, we submitted and obtained usable genotyping data on 2184 patients 	and 1155 controls from the Center for Inherited Disease Research (<a href="http://www.cidr.jhmi.edu/" target="_blank">CIDR</a>).</p>]]>
	</Description>
	<StudyInEx><![CDATA[
<p>Inclusion criteria:<br/> 	1.  Affected with geographic atrophy, neovascularization, or large drusen in at least one eye.  If any of the above are only 	found in one eye, then the evidence of drusen, pigment changes must be found in the fellow eye.<br/> 	2.  Control patients have been examined and found to have no more than 5 hard drusen and are over the age of 50 (Mayo clinic 	cohort) or small drusen and pigment changes in one eye only and are over the age of 60 (UMich and UPenn clinic 	cohorts).<br/> 	</p> 	<p>Exclusion criteria:<br/> 	1.  Evidence or history of severe macular disease or vision loss before the age of 40, or diagnosis with symptoms 	consistent with a juvenile macular or retinal degeneration, or macular damage resulting from ocular trauma, retinal detachment, 	high myopia, chorioretinal infection, or inflammatory disease, or choroidal dystrophy or other retinal insult in which the 	fundus was not gradable. 	</p>]]>
	</StudyInEx>
	<StudyProjects>
		<Project/>
	</StudyProjects>
	<Publications>
		<Publication>
			<Pubmed pmid="20385819"/>
		</Publication>
		<Publication>
			<Pubmed pmid="14968411"/>
		</Publication>
		<Publication>
			<Pubmed pmid="15111581"/>
		</Publication>
		<Publication>
			<Pubmed pmid="15987700"/>
		</Publication>
		<Publication>
			<Pubmed pmid="15761121"/>
		</Publication>
		<Publication>
			<Pubmed pmid="15829498"/>
		</Publication>
		<Publication>
			<Pubmed pmid="15895326"/>
		</Publication>
		<Publication>
			<Pubmed pmid="16225921"/>
		</Publication>
		<Publication>
			<Pubmed pmid="16936733"/>
		</Publication>
		<Publication>
			<Pubmed pmid="17884985"/>
		</Publication>
		<Publication>
			<Pubmed pmid="17911160"/>
		</Publication>
		<Publication>
			<Pubmed pmid="18369057"/>
		</Publication>
		<Publication>
			<Pubmed pmid="18385087"/>
		</Publication>
		<Publication>
			<Pubmed pmid="19043567"/>
		</Publication>
		<Publication>
			<Pubmed pmid="19169411"/>
		</Publication>
		<Publication>
			<Pubmed pmid="19469037"/>
		</Publication>
		<Publication>
			<Pubmed pmid="19405847"/>
		</Publication>
	</Publications>
	<Diseases>
		<Disease vocab_source="MESH" vocab_term="Macular Degeneration"/>
	</Diseases>
	<Attributions>
		<Header title="Principal Investigator">
			<AttName>Anand Swaroop, PhD</AttName>
			<Institution>National Eye Institute, National Institutes of Health, Bethesda, MD, USA; University of Michigan, Ann Arbor, MI, USA</Institution>
		</Header>
		<Header title="Co-Principal Investigators">
			<AttName>Gon&#231;alo Abecasis, PhD</AttName>
			<Institution>University of Michigan, Ann Arbor, MI, USA</Institution>
		</Header>
		<Header title="Co-Principal Investigators">
			<AttName>Dwight Stambolian, MD, PhD</AttName>
			<Institution>University of Pennsylvania, Philadelphia, PA, USA</Institution>
		</Header>
		<Header title="Co-Principal Investigators">
			<AttName>Albert Edwards, MD, PhD</AttName>
			<Institution>Mayo Clinic, Rochester, MN, USA</Institution>
		</Header>
		<Header title="Co-Investigators">
			<AttName>John Heckenlively, MD</AttName>
			<Institution>University of Michigan, Ann Arbor, MI, USA</Institution>
		</Header>
		<Header title="Co-Investigators">
			<AttName>Emily Chew, MD</AttName>
			<Institution>National Eye Institute, National Institutes of Health, Bethesda, MD, USA</Institution>
		</Header>
		<Header title="Co-Investigators">
			<AttName>William Brown, OD</AttName>
			<Institution>Mayo Clinic, Rochester, MN, USA</Institution>
		</Header>
		<Header title="Co-Investigators">
			<AttName>Keith Baratz, MD</AttName>
			<Institution>Mayo Clinic, Rochester, MN, USA</Institution>
		</Header>
		<Header title="Biostatisticians">
			<AttName>Wei Chen, PhD</AttName>
			<Institution>University of Michigan, Ann Arbor, MI, USA</Institution>
		</Header>
		<Header title="Biostatisticians">
			<AttName>Euijung Ryu, PhD</AttName>
			<Institution>Mayo Clinic, Rochester, MN, USA</Institution>
		</Header>
		<Header title="Biostatisticians">
			<AttName>Alice Henning, MS</AttName>
			<Institution>The EMMES Corporation, Rockville, MD, USA</Institution>
		</Header>
		<Header title="Coordinator">
			<AttName>Kari Branham, MS</AttName>
			<Institution>University of Michigan, Ann Arbor, MI, USA</Institution>
		</Header>
		<Header title="Research Technologist">
			<AttName>Mohammad Othman, PhD</AttName>
			<Institution>University of Michigan, Ann Arbor, MI, USA</Institution>
		</Header>
		<Header title="Research Technologist">
			<AttName>Nirubol Tosakulwong, BS</AttName>
			<Institution>Mayo Clinic, Rochester, MN, USA</Institution>
		</Header>
		<Header title="Funding Source for Genotyping">
			<AttName>HHSN268200782096C. NIH contract &quot;High throughput genotyping for studying the genetic contributions to human disease&quot;</AttName>
			<Institution>National Institutes of Health, Bethesda, MD, USA</Institution>
		</Header>
	</Attributions>
	<DisplayPublicSummary>yes</DisplayPublicSummary>
	<StudyHistory><![CDATA[
<p>The University of Michigan genetic study of AMD was started in 1998 by Dr. Anand Swaroop with the goal of 	identifying susceptibility loci for AMD.  Affected patients were enrolled primarily from the retina clinic of 	the Kellogg Eye Center with the help of clinicians and staff.  The control participants were 	enrolled primarily from the general ophthalmology clinics of the Kellogg Eye Center.  After the enrollment of affected 	probands, we sought to enroll affected and unaffected family members.  To date, more than 2300 affected 	and unaffected subjects have been enrolled in the study.</p> 	<p>The University of Michigan genetic studies of AMD have resulted in several peer-reviewed manuscripts, notably a 	whole-genome linkage scan for age-related macular degeneration (<a href="http://www.ncbi.nlm.nih.gov/pubmed/14968411">Abecasis et al., 2004</a>) 	and a joint-analysis of several linkage scans (<a href="http://www.ncbi.nlm.nih.gov/pubmed/15987700">Fisher et al., 2005</a>), a 	dissection of the roles of complement factor H (<a href="http://www.ncbi.nlm.nih.gov/pubmed/15895326">Zareparsi et al., 2005a</a>) and 	TLR4 (<a href="http://www.ncbi.nlm.nih.gov/pubmed/15829498">Zareparsi et al., 2005b</a>), and recent detailed analysis of the 	complement factor H locus (<a href="http://www.ncbi.nlm.nih.gov/pubmed/16936733">Li et al., 2006</a>) and 	LOC387715/ARMS2 locus (<a href="http://www.ncbi.nlm.nih.gov/pubmed/17884985">Kanda et al., 2007</a>) among others.</p> 	<p>For the University of Pennsylvania cohort, subjects were ascertained through the ophthalmology practices of the 	University of Pennsylvania (Dr. Dwight Stambolian and colleagues) as well as subjects who participated in the 	clinical trial of the CAPT study.</p> 	<p>The Mayo subjects were enrolled from the practices of Dr. Albert Edwards and selected colleagues from Dallas, TX 	and Rochester, MN starting in 1998.  The subjects have been used in a number of studies and contributed to one of the initial 	reports of association between macular degeneration and the CFH locus (<a href="http://www.ncbi.nlm.nih.gov/pubmed/15761121">Edwards et 	al., 2005,</a>, <a href="http://www.ncbi.nlm.nih.gov/pubmed/18385087">2008</a>, 	<a href="http://www.ncbi.nlm.nih.gov/pubmed/19469037">2009</a>; <a href="http://www.ncbi.nlm.nih.gov/pubmed/19169411">Park et al., 2009</a>).</p>]]>
	</StudyHistory>
	<ConsentGroups>
		<ConsentGroup groupNum="0" shortName="NRUP" longName="Subjects did not participate in the study, did not complete a consent document and are included only for the pedigree structure and/or genotype controls, such as HapMap subjects."/>
		<ConsentGroup groupNum="1" shortName="GRU" longName="General Research Use"/>
		<ConsentGroup groupNum="2" shortName="EDO" longName="Eye Disease Research Use Only"/>
	</ConsentGroups>
</Configuration>

  <AuthorizedAccess>
    <DacInfo ssDacId="0">
      <DacName>NEI</DacName>
      <DacFullName>National Eye Institute</DacFullName>
      <DacEmail>0</DacEmail>
      <DacPhone></DacPhone>
      <DacUrl>http://grants.nih.gov/grants/gwas</DacUrl>
    </DacInfo>
    <Policy Policy_ID="phs000182.v2.p1_policy" ref_ssDacId="0">
      <DisplayResearchStatement>yes</DisplayResearchStatement>
      <DisplayPublicSummary>yes</DisplayPublicSummary>
      <EmbargoLength>12</EmbargoLength>
      <YearsUntilRenewal>1</YearsUntilRenewal>
      <WeeksCancelRequest>8</WeeksCancelRequest>
      <PdfSupplementReqired>no</PdfSupplementReqired>
      <AcknowledgementText>
        <para>
          http://dbgap.ncbi.nlm.nih.gov/aa/wga.cgi?page=DUC&amp;view_pdf&amp;stacc=phs000182.v2.p1
        </para>
      </AcknowledgementText>
      <DocumentSet>
        <DataUseCertificate Label="Data Use Certificate" FilePath="https://dbgap.ncbi.nlm.nih.gov/aa/wga.cgi?page=DUC&amp;view_pdf&amp;stacc=phs000182.v2.p1" FileName="NEI-AMD_DUC_general.pdf"/>
      </DocumentSet>
    </Policy>
    <ConsentGroups>
      <ParticipantSet groupNum-REF="1">
        <ConsentName>General Research Use</ConsentName>
        <ConsentAbbrev>GRU</ConsentAbbrev>
        <UseLimitation>Study participant consented to general research use. These participants submitted a genetic specimen and the genetic specimen data for these participants can be obtained by contacting the PI of the study or NEI DAC (Data Access Committee). This consent group does not require IRB approval.</UseLimitation>
        <IrbRequired>No</IrbRequired>
      </ParticipantSet>
      <ParticipantSet groupNum-REF="2">
        <ConsentName>Eye Disease Research Only</ConsentName>
        <ConsentAbbrev>EDO</ConsentAbbrev>
        <UseLimitation>Study participants submitted a genetic specimen but consented to it being used for eye disease research only. Therefore, genetic specimen data can NOT be linked to all data collected during the course of this study. Only a subset of clinical data relevant for eye disease research is linked to genetic specimen data from these participants. 
This consent group does not require IRB approval.</UseLimitation>
        <IrbRequired>No</IrbRequired>
      </ParticipantSet>
    </ConsentGroups>
  </AuthorizedAccess>

<Analyses>
	<Analysis pha="2869" genomeBuild="37.1" snpBuild="132" analysisType="">
		<Description><![CDATA[
 Genome-wide genotyping data were produced using the Illumina HumanCNV370v1_C array platform and filtered using the following criteria: 1) per sample call rate &#8805;  98%, 2) SNP minor allele frequency &#8805;  1%, 3) SNP call rate &#8805;  95%, 4) SNP HWE p-value &#8805;  1x10<sup>-6</sup>, 5) less than two SNP duplicate errors, 6) less than three SNP parent-parent-child trio errors, resulting in  a set of 333313 SNPs across 3309 unrelated samples.  Genome-wide association scan has been <font color="red">pre-computed by NCBI</font>.
		]]></Description>
		<Method>Genome-wide association</Method>
		<GtyPlatform probeNum="370404" snpBatchId="1047132">
			<Vendor>Illumina</Vendor>
			<VendorURL>similar to 16 but alleles from dbSNP set and complete set</VendorURL>
			<Platform>HumanCNV370v1-Complete</Platform>
		</GtyPlatform>
		<Comment></Comment>
	</Analysis>
	<Analysis pha="2890" genomeBuild="37.1" snpBuild="132" analysisType="">
		<Description><![CDATA[
 Genome-wide genotyping data were produced using the Illumina HumanCNV370v1_C array platform and filtered using the following criteria: 1) per sample call rate &#8805; 99%, 2) SNP minor allele frequency &#8805; 1%, 3) SNP call rate &#8805; 95%, 4) SNP HWE p-value &#8805; 1x10<sup>-6</sup>, 5) removing unexpected relatives, resulting in a set of 324067 autosomal SNPs across 3307 unrelated samples (2157 cases and 1150 controls).  
		]]></Description>
		<Method>categorical analysis</Method>
		<GtyPlatform probeNum="370404" snpBatchId="1047132">
			<Vendor>Illumina</Vendor>
			<VendorURL>similar to 16 but alleles from dbSNP set and complete set</VendorURL>
			<Platform>HumanCNV370v1-Complete</Platform>
		</GtyPlatform>
		<Comment></Comment>
	</Analysis>
</Analyses>

</Study>

</Studies>

</GaPExchange>
